Physician profile
David Parker
NPI 1003887597
$13,875.44
in general payments reported to CMS, 2019-2025
47 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,092 · 2020: $1,705 · 2021: $2,743 · 2022: $1,857 · 2023: $2,369 · 2024: $2,248 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,477.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,475.50 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,728.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,077.22 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $983.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $936.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $624.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $614.74 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $480.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $455.33 | 2019-2025 | |
| Esperion Therapeutics, INC. | $433.52 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $421.35 | 2019-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.62 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $346.65 | 2019-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $255.92 | 2019-2024 | Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $254.50 | 2022-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.